Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults
AIDS, Volume 15, No. 16, Year 2001
Notification
URL copied to clipboard!
Description
Background: Treatment of latent infection is needed to protect HIV-infected individuais against tuberculosis. A previous report addressed short-term efficacy of three regimens in HIV-infected adults. We now report on long-term efficacy of the study regimens. Methods: Three daily self-administered regimens were compared in a randomized placebo-controlled trial in 2736 purified protein derivative (PPD)-positive and anergic HIV-infected adults. PPD-positive subjects were treated with isoniazid (INH) for 6 months (6H), INH plus rifampicin for 3 months (3HR), INH plus rifampicin and pyrazinamide for 3 months (3HRZ), or placebo for 6 months. Anergic subjects were randomized to 6H or placebo. Results: 6H initially protected against tuberculosis in PPD-positive individuals; however, benefit was lost within the first year of treatment. Sustained benefit was observed in persons receiving 3HR and 3HRZ. In a Cox regression analysis, the adjusted relative risk for tuberculosis compared with placebo was 0.67 [95% confidence interval (CI), 0.42-1.07] for 6H, 0.49 (95% Cl, 0.29-0.82) for 3HR, and 0.41 (95% Cl, 0.22-0.76) for 3HRZ. When the rifampicin-containing regimens were combined, the adjusted relative risk for tuberculosis compared with placebo was 0.46 (95% Cl, 0.29-0.71). Among anergic subjects, a modest degree of protection with 6H was present (adjusted relative risk, 0.61; 95% Cl, 0.32-1.16). Treatment of latent tuberculosis infection had no effect on mortality. Conclusion: Six months of INH provided short-term protection against tuberculosis in PPD-positive HIV-infected adults. Three month regimens including INH plus rifampicin or INH, rifampicin and pyrazinamide provided sustained protection for up to 3 years. © 2001 Lippincott Williams and Wilkins.
Authors & Co-Authors
Johnson, John L.
United States, Cleveland
University Hospitals Case Medical Center
United States, Cleveland
Case Western Reserve University
Okwera, Alphonse
Sierra Leone
National Leprosy and Tuberculosis Control Programme
Hom, David L.
United States, Cleveland
University Hospitals Case Medical Center
Mayanja, Harriet K.
Uganda, Kampala
Makerere University
Kityo, Cissy Mutuluuza
Uganda, Kampala
Joint Clinical Research Center Uganda
Nsubuga, Peter
Sierra Leone
National Leprosy and Tuberculosis Control Programme
Nakibali, Joseph G.
Sierra Leone
National Leprosy and Tuberculosis Control Programme
Loughlin, Anita M.
United States, Cleveland
University Hospitals Case Medical Center
Yun, Hyun
United States, Cleveland
University Hospitals Case Medical Center
Mugyenyi, Peter N.
Uganda, Kampala
Joint Clinical Research Center Uganda
Vernon, Andrew A.
United States, Atlanta
Centers for Disease Control and Prevention
Mugerwa, Roy D.
Uganda, Kampala
Makerere University
Ellner, Jerrold J.
United States, Cleveland
University Hospitals Case Medical Center
Whalen, Christopher Curtis
United States, Cleveland
Case Western Reserve University
Statistics
Citations: 159
Authors: 14
Affiliations: 6
Identifiers
Doi:
10.1097/00002030-200111090-00009
Research Areas
Infectious Diseases
Study Approach
Quantitative